Literature DB >> 11853586

[A study on the effect of vitreous cavity length in primary ametropia].

J Li1, F Wang, H Ji.   

Abstract

OBJECTIVE: To study the nature of primary ametropia and disclose the actions of ocular refractive components, especially the length of vitreous cavity, on primary ametropia.
METHODS: The refractive state, corneal refractive power (CP), anterior ocular segment length (ASL), vitreous length (VL) and ocular axial length (AL) were measured for 1 336 eyes, including 523 hyperopic eyes, 199 emmetropic eyes and 614 myopic eyes. The relationships of these elements were studied.
RESULTS: CP had no effect on the refractive state. There was no significant difference between CP of these three refractive groups (hyperopia vs. emmetropia and emmetropia vs. myopia) (P > 0.05). The test of normality showed that the distribution of CP was normal in each refractive state. Case control study of paired sample revealed that ASL did not change regularly with the change of refraction, while VL changed progressively with the change of refraction and there was significant difference between each pair of groups (F = 204.29, P < 0.01). The study of the relationship with matching t test between AL and VL showed that the change amount of AL and VL was nearly the same, that was, the growth of AL was about the same as the growth of VL (P > 0.05). Analysis of correlation and regression showed that these two elements were highly correlated, the coefficient of correlation being 0.879.
CONCLUSION: VL determines AL and finally determines refractive state. VL is the most important element in determining primary ametropia while the anterior eye segment has no significant contribution.

Entities:  

Mesh:

Year:  2000        PMID: 11853586

Source DB:  PubMed          Journal:  Zhonghua Yan Ke Za Zhi        ISSN: 0412-4081


  1 in total

1.  Effects of scleral encircling surgery on vitreous cavity length and diopter.

Authors:  Zi-Cheng Zhu; Gen-Jie Ke; Yue-Chun Wen; Zhang-You Wu
Journal:  Int J Ophthalmol       Date:  2016-04-18       Impact factor: 1.779

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.